ADMA BIOLOGICS, INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
ADMA BIOLOGICS, INC. (ADMA) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $6.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-05
- ADMA BIOLOGICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $6.13M, a 23.61% increase year-over-year.
- ADMA BIOLOGICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $6.33M, a 36.87% increase year-over-year.
- ADMA BIOLOGICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $5.05M, a 58.76% increase year-over-year.
- ADMA BIOLOGICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $4.96M, a 73.35% increase year-over-year.
- ADMA BIOLOGICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $20.03M, a 47.08% increase from fiscal 2024.
- ADMA BIOLOGICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $13.62M, a 120.07% increase from fiscal 2023.
- ADMA BIOLOGICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $6.19M, a 18.64% increase from fiscal 2022.
- ADMA BIOLOGICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $5.21M, a 49.51% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6.13M 10-Q · filed 2026-08-05 | $12.46M derived: sum of 2 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $6.33M 10-Q · filed 2026-08-05 | |||||
| 2025-12-31 | $20.03M 10-K · filed 2026-02-25 | |||||
| 2025-09-30 | $5.05M 10-Q · filed 2025-11-05 | $10.01M derived: sum of 2 quarters · filed 2026-08-05 | $14.63M derived: sum of 3 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $4.96M 10-Q · filed 2026-08-05 | $9.59M derived: sum of 2 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $4.62M 10-Q · filed 2026-08-05 | |||||
| 2024-12-31 | $13.62M 10-K · filed 2026-02-25 | |||||
| 2024-09-30 | $3.18M 10-Q · filed 2025-11-05 | $6.04M derived: sum of 2 quarters · filed 2025-11-05 | $8.18M derived: sum of 3 quarters · filed 2025-11-05 | |||
| 2024-06-30 | $2.86M 10-Q · filed 2025-11-05 | $5.00M derived: sum of 2 quarters · filed 2025-11-05 | ||||
| 2024-03-31 | $2.14M 10-Q · filed 2025-11-05 | |||||
| 2023-12-31 | $6.19M 10-K · filed 2026-02-25 | |||||
| 2023-09-30 | $1.70M 10-Q · filed 2024-11-07 | $1.69M 10-Q · filed 2023-11-08 | $3.33M derived: sum of 2 quarters · filed 2024-11-07 | $4.44M derived: sum of 3 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $1.64M 10-Q · filed 2024-11-07 | $1.64M 10-Q · filed 2023-08-09 | $2.75M derived: sum of 2 quarters · filed 2024-11-07 | |||
| 2023-03-31 | $1.11M 10-Q · filed 2024-11-07 | $1.11M 10-Q · filed 2023-05-10 | ||||
| 2022-12-31 | $5.21M 10-K · filed 2025-03-18 | $5.21M 10-K · filed 2023-03-23 | ||||
| 2022-09-30 | $1.31M 10-Q · filed 2023-11-08 | $2.50M derived: sum of 2 quarters · filed 2023-11-08 | $4.15M derived: sum of 3 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $1.19M 10-Q · filed 2023-11-08 | $2.83M derived: sum of 2 quarters · filed 2023-11-08 | ||||
| 2022-03-31 | $1.64M 10-Q · filed 2023-11-08 | |||||
| 2021-12-31 | $3.49M 10-K · filed 2024-02-28 | $3.49M 10-K · filed 2022-03-24 | ||||
| 2021-09-30 | $688.27K 10-Q · filed 2022-11-09 | $1.49M derived: sum of 2 quarters · filed 2022-11-09 | $2.27M derived: sum of 3 quarters · filed 2022-11-09 | |||
| 2021-06-30 | $805.19K 10-Q · filed 2022-11-09 | $1.59M derived: sum of 2 quarters · filed 2022-11-09 | ||||
| 2021-03-31 | $781.40K 10-Q · filed 2022-11-09 | |||||
| 2020-12-31 | $2.86M 10-K · filed 2022-03-24 | |||||
| 2020-09-30 | $774.78K 10-Q · filed 2021-11-10 | $1.49M derived: sum of 2 quarters · filed 2021-11-10 | $2.17M derived: sum of 3 quarters · filed 2021-11-10 | |||
| 2020-06-30 | $715.61K 10-Q · filed 2021-11-10 | $1.39M derived: sum of 2 quarters · filed 2021-11-10 | ||||
| 2020-03-31 | $676.55K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |